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Background: The EVEREST II randomized trial showed that percutaneous repair of the
mitral valve with the MitraClip® device (Abbott Vascular, Santa Clara, CA) reduced
mitral regurgitation less completely than conventional surgery, but was associated with
superior safety and similar clinical outcomes at 12 months. The potential cost-
effectiveness (CE) of the MitraClip procedure compared with mitral valve surgery is not
presently known.
Methods: We conducted a 12-month U.S. CE analysis comparing the MitraClip
procedure with mitral valve surgery based on the EVEREST II trial. Index admission
costs were calculated using hospital billing data or estimated using regression models.
Costs for follow-up hospitalizations were estimated based on Medicare reimbursement.
Resource-based costs were also included for rehabilitative and long-term care services.
SF-36 data, collected at baseline, 1 and 12 months, was used to calculate quality-adjusted
life years (QALYs). Results were assessed in a primary modified intention to treat (mITT)
population excluding randomized but not treated patients.
Results: Results were sensitive to assumptions on the duration of QOL benefit with
MitraClip relative to surgery (present at 1 but not 12 months), the price of the MitraClip
device, and the analytic population. In our base case the MitraClip strategy slightly
increased QALYs through 12 months (0.015) At the study price of $18,000 the clip
strategy reduced costs by $2,200/patient, making MitraClip economically dominant. At a
clip price of $26,200 (approximate European sales price), overall costs were higher with
the clip strategy by $6,192 and the incremental CE ratio was unfavorable ($400,000 per
QALY gained). In a sensitivity analysis limiting to patients with acute procedural success
(per protocol population), the QALY gain was larger (0.041), the cost-offsets with the clip
greater, and cost-effectiveness more favorable (dominant at a MitraClip price of $18,000,
$54,000 per QALY gained at $26,200).
Conclusions: The potential cost-effectiveness of MitraClip compared with mitral valve
surgery in EVEREST II varied depending primarily on MitraClip price and acute
procedural success.
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Background: Mitral valve surgery is generally indicated for patients with severe
degenerative mitral regurgitation (DMR). However, surgical correction of MR may not
always be possible in high surgical risk patients. The purpose of this analysis is to describe
clinical benefit including improvements in left ventricular (LV) size and function
observed following treatment with the MitraClip device (Abbott Vascular, Menlo Park,
CA) in high surgical risk patients with DMR.
Methods: EVEREST II High Risk Study and REALISM Continued Access Registry
patients had significant MR (3	/4	) and were deemed high risk for surgery as
determined by a STS predicted surgical mortality 12% or surgeon assessment. Clinical
measures including NYHA Functional Class, quality of life (QOL) and hospitalizations
for CHF as well as echocardiographic measurements analyzed by an independent core lab
were evaluated.
Results: 62 high surgical risk DMR patients underwent a MitraClip procedure with a
94% implant rate. Patients were elderly (mean age 838 yrs) with significant comor-
bidities (CHF 100%, CAD 75%, prior cardiac surgery 47%). The mean predicted surgical
mortality by STS calculator was 14.89.1%. Observed mortality at 30 days and 12
months was 6.5% and 25.8%, respectively. 37 patients had matched echocardiograms
between Baseline and 12 months, of which 78% achieved MR severity 2	. Clinical
benefit was demonstrated at 12 months with significant improvements in LV volumes,
NYHA Functional Class, and QOL (Table). Compared to 12 months prior the MitraClip
procedure, the annual rate of CHF hospitalizations decreased 77% in the 12 months
post-procedure.
MeanSD (N) LVEDV (ml) LVESV (ml)
Baseline 13540 (51) 5126 (51)
30 Days† 12341 (51) 5327 (51)
Change from Baseline to 30 Days -1216 213
p-value 0.0001 0.32
Baseline 13743 (35) 5129 (35)
12 Months 11838 (35) 4925 (35)
Change from Baseline to 12
Months
-1920 -214
p-value 0.0001 0.38
LV Ejection Fraction (%)
NYHA Functional
Class I/II (%)
638 (51) 18 (55)
5810 (51) 73 (55)
-58 55
0.0001 0.0001
649 (35) 21 (39)
5910 (35) 85 (39)
-57 64
0.0004 0.0001
Quality of Life
PCS Score
Quality of Life
MCS Score
3110 (51) 4912 (51)
3810 (51) 5011 (51)
710 112
0.0001 0.59
3310 (34) 4913 (34)
3912 (34) 5310 (34)
69 412
0.0005 0.085
†Echocardiographic measures were evaluated at Discharge
PCS  Physical Component Summary, MCS  Mental Component Summary
Conclusions: The MitraClip procedure resulted in significant improvements in MR
severity, LV reverse remodeling, and clinical outcomes and is an important therapeutic
option for patients with significant degenerative MR who are not suitable candidates for
surgery.
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Background: EVEREST II is a prospective multi-center RCT comparing safety and
effectiveness of the MitraClip System with mitral valve (MV) surgery in the treatment of
severe (3	 or 4	) mitral regurgitation (MR). We report outcomes at 3 years to evaluate
durability of clinical endpoints and changes in MR severity and left ventricular (LV)
volumes.
Methods: 279 patients, randomized 2:1 to transcatheter MitraClip treatment or surgery
were enrolled at 37 sites in North America. Each patient had core lab assessed
echocardiograms prior to enrollment. Clinical benefit was assessed at 3 years by measures
of LV function, NYHA Functional Class (NYHA-FC) and freedom from mortality and
MV surgery or re-operation.
Results: Mean age was 67 years; baseline LV ejection fraction was 60%. Half were in
NYHA-FC III/IV and 73% had degenerative MR. Through 3 years, 24 MitraClip and 11
surgery patients withdrew. Of 258 treated patients, Kaplan-Meier (KM) estimate of
freedom from mortality at 3 years was 87% in MitraClip and 85% in surgery groups. KM
estimate of freedom from surgery was 78% in MitraClip patients and freedom from
re-operation was 94% in surgery patients, both unchanged from 1 year. In patients with
matched data, MR severity was  2	 in 84% of MitraClip and 96% of surgery groups.
Compared to baseline, LV end-diastolic volumes at 3 years decreased by 29 mL and 44
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mL in MitraClip and surgery groups respectively; LV end-systolic volumes decreased by
6 mL and 11 mL respectively. 97% of MitraClip and 98% of surgery patients were
NYHA-FC I/II.
Conclusions: Both the MitraClip device and MV surgery confer clinical benefits through
3 years similar to EVEREST II results at 1 year and 2 years, with sustained reduction in
MR and sustained improvement in LV volumes and NYHA-FC. Although there is a 22%
rate of surgery within 6 months post-index MitraClip procedure, this rate remains stable
thereafter. Despite larger reductions in LV volumes and MR severity in the surgery group,
both groups experienced similar levels of sustained improvement in NYHA-FC at 3 years.
The MitraClip device may be considered a transcatheter therapeutic option for select
patients with severe MR.
TCT-789
Optimizing plugs size for transcatheter paravalvular leak closure with
Amplatzer Vascular Plug III devices
Grzegorz Smolka1, Piotr Pysz1, Ewa Peszek-Przybyla1, Przemyslaw Zurek1,
Zbigniew Gasior2, Andrzej Ochala2
1Medical University of Silesia Hospital, Katowice, Poland, 2Medical University of
Silesia, Katowice, Poland
Background: Transcatheter paravalvular leak closure (TPVLC) has become a well-
established alternative to reoperation. Implantation of multiple smaller plugs is postulated
to outperform a single large one. Still, the procedural success pivots on optimal choice of
occluding devices, which has not been standardized as yet.
Methods: We enrolled 16 patients with mitral (n10) or aortic paravalvular leak (PVL)
scheduled for TPVLC. In each case PVL channel area (PVLCA) was estimated according
to its minimum and maximum diameters in the plane parallel to prosthesis’ sewing ring
with use of transesophageal echocardiography (TEE). We also calculated the middle
module area (MMA) for different sizes of AVPs III according to their length and width
as provided by manufacturer. Then, in a 1-stage procedure, 2 AVPs III of similar size were
implanted into each PVL either simultaneously or sequentially. Their added MMAs were
aimed to exceed the targeted PVLCA by 10-30%.
Results: The mean ratio of maximum to minimum PVL diameter was 2.32. The mean
estimated PVLCA [mm2] was 60.7 with median of 44.5, minimum 24 and maximum of
148. The mean value of occluders’ added MMAs exceeded corresponding PVLCA by
27.7%. Optimal effect defined by total occlusion or trivial residual PVL by TEE was
achieved in 13 patients. When technical challenges disabled the intended oversizing
(n3) a moderate residual PVL was present - see Figure 1.
Conclusions: Implantation of 2 AVPs III with approximately 30% area oversizing
ensures complete TPVLC in patients with oblong PVL.
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Background: Mitral regurgitation (MR) of functional vs. degenerative origin are
different morphological entities that have mostly been grouped together in studies
published to date on MitraClip therapy. We sought to identify factors predicting the
long-term clinical outcome following MitraClip implantation according to the underlying
etiology.
Methods: By April 2012, 270 consecutive patients (74  9 years, 172 men) with
significant MR not amenable to surgery underwent MitraClip therapy at our center.
Functional (FMR) and degenerative/mixed MR (DMR) were present in 184 (68%) and 86
patients, respectively. We performed survival analyses (Kaplan-Meier, Cox regression) of
230 patients followed.
Results: Cumulative survival at 2 years did not differ between DMR and FMR patients
(65.3 [95% CI, 55.7-74.9]% vs. 60.5 [45.7-75.4]%, p0.855); however, at 2 years,
rehospitalizations occurred significantly more often in FMR patients (70.5 [59.3-81.7]%
vs. 49.6 [37.3-62.0]%, p0.023 by 12-month-landmark analysis) and mitral valve surgery
was needed significantly more often in DMR patients (20.0 [9.2-30.9]% vs. 5.0
[0.7-9.2]%, p0.002). Uni- and multivariate Cox regression revealed that for both FMR
and DMR left ventricular dilatation was independently predictive of rehospitalization.
Independent predictors of reintervention were an anterior mitral leaflet length30 mm for
DMR, and an eccentric MR jet and increasing left atrial area for FMR.
Conclusions: As shown for this high-risk patient population, MR etiology did not impact
on survival following MitraClip, however, clear differences between FMR and DMR were
observed with respect to rehospitalization and reintervention: Whereras treatment of DMR
is linked to increased reinterventions, the increased rate of rehospitalization in patients
treated for FMR reflects the increased degree of LV dysfunction.
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Background: Corrective surgery for functional mitral regurgitation (FMR) has proven
beneficial in that it improves NYHA functional class and induces reverse left ventricular
remodeling. However, proof of survival benefit is pending. Percutaneous techniques of
mitral valve repair (MVR) may become a viable treatment alternative for high-risk
patients with severe FMR.
Methods: We retrospectively analyzed our prospective hospital database of patients with
severe FMR undergoing percutaneous treatment using the MitraClip device or surgical
MVR. Patient characteristics and acute and 6-month hemodynamic and clinical outcomes
are reported.
Results: 95 patients were treated using the MitraClip device while 76 patients underwent
isolated surgical MVR for FMR. Patients undergoing MitraClip treatment were signifi-
cantly older (mean72.48.1vs.64.511.4 years,p0.001), had a lower left ventricular
ejection fraction (mean36.212.5%vs.42.116.2%,p0.014), and were generally more
high-risk, with a significantly higher mean logEuroSCORE compared to surgical
candidates (33.718.7vs.10.18.7%,p0.001). Procedural success was 95.8% (91/95)
for MitraClip treatment and 93.4% (71/76) for surgery (p0.491). 30-day mortality was
4.2% (4/95) and 2.6% (2/76;p0.557) and mean grade of residual MR was 1.40.8 and
0.20.4 (p0.001) after MitraClip treatment and surgical MVR respectively. Unadjusted
survival rates after 6 months were 87% and 96% for MitraClip and surgical treatment
respectively. However, after multivariate regression analysis and adjustment for baseline
differences, survival differences were no longer statistically significant (p0.358).
Conclusions: Patients with FMR undergoing surgery differ significantly from those
considered for percutaneous therapy. Surgery was more effective compared to MitraClip
in reducing MR. However, a large proportion of patients benefits from percutaneous
intervention with sustained MR2	 at 6 months. Especially for elderly patients with
reduced left ventricular function and relevant comorbidities, MitraClip therapy seems to
be an adequate alternative to surgery. Assessment, treatment and postprocedural care of
patients by an interdisciplinary team is of paramount importance for clinical success.
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Background: Due to the implantation of one or more MitraClips in patients with mitral
valve regurgitation, a decrease in mitral valve area (MVA) is created, which has not been
shown to result in clinical significant mitral stenosis. However mitral inflow patterns were
only measured in these patients during resting conditions. Therefore we aimed to
investigate the effect of MitraClip implantation on mitral valve pressure gradient (MVPG)
during exercise.
Methods: We included 23 patients with symptomatic severe mitral regurgitation (age
768 years, 44% male) who underwent MitraClip implantation with placement of one or
more clips. Transthoracic echocardiography was performed pre-procedural and at follow
up after MitraClip implantation (median follow up: 13 months) to measure the mean and
maximum MVPG with continuous wave Doppler in rest and during bicycle exercise test.
Results: NYHA functional class was significantly decreased after MitraClip from class
III to II (p0.001). Following MitraClip implantation the mean MVPG increased from
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